WO2014139809A1 - Verfahren und kit zur herstellung von biomaterial zur geweberegeneration - Google Patents
Verfahren und kit zur herstellung von biomaterial zur geweberegeneration Download PDFInfo
- Publication number
- WO2014139809A1 WO2014139809A1 PCT/EP2014/054005 EP2014054005W WO2014139809A1 WO 2014139809 A1 WO2014139809 A1 WO 2014139809A1 EP 2014054005 W EP2014054005 W EP 2014054005W WO 2014139809 A1 WO2014139809 A1 WO 2014139809A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- rinsing solution
- rinsing
- edta
- solution
- Prior art date
Links
- 239000012620 biological material Substances 0.000 title claims abstract description 85
- 230000017423 tissue regeneration Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 41
- 239000003102 growth factor Substances 0.000 claims abstract description 186
- 239000000463 material Substances 0.000 claims abstract description 83
- 239000012487 rinsing solution Substances 0.000 claims abstract description 76
- 241001465754 Metazoa Species 0.000 claims abstract description 51
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 230000002328 demineralizing effect Effects 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000011068 loading method Methods 0.000 claims abstract description 9
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 133
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 91
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 claims description 75
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 31
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 20
- 229920000669 heparin Polymers 0.000 claims description 20
- 229960002897 heparin Drugs 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 230000015556 catabolic process Effects 0.000 claims description 19
- 238000006731 degradation reaction Methods 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 13
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 239000002738 chelating agent Substances 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 229920000570 polyether Polymers 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 9
- 102000009123 Fibrin Human genes 0.000 claims description 8
- 108010073385 Fibrin Proteins 0.000 claims description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 8
- 229920000954 Polyglycolide Polymers 0.000 claims description 8
- 150000007513 acids Chemical class 0.000 claims description 8
- 229950003499 fibrin Drugs 0.000 claims description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 8
- 239000004633 polyglycolic acid Substances 0.000 claims description 8
- 239000004626 polylactic acid Substances 0.000 claims description 8
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 7
- 239000007857 degradation product Substances 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical class [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 description 89
- 210000004268 dentin Anatomy 0.000 description 44
- 108010009583 Transforming Growth Factors Proteins 0.000 description 37
- 102000009618 Transforming Growth Factors Human genes 0.000 description 37
- 210000004262 dental pulp cavity Anatomy 0.000 description 36
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 32
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 32
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 30
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 30
- 239000000499 gel Substances 0.000 description 28
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 229940126864 fibroblast growth factor Drugs 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 17
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 17
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 14
- 102000013275 Somatomedins Human genes 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 108010066486 EGF Family of Proteins Proteins 0.000 description 13
- 102000018386 EGF Family of Proteins Human genes 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 12
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 9
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 8
- 229960003260 chlorhexidine Drugs 0.000 description 8
- 229960004106 citric acid Drugs 0.000 description 8
- 239000005708 Sodium hypochlorite Substances 0.000 description 7
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 7
- 229940093476 ethylene glycol Drugs 0.000 description 7
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 7
- 239000000017 hydrogel Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008467 tissue growth Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 210000005258 dental pulp stem cell Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000009772 tissue formation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000005115 demineralization Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- -1 of sodium Chemical class 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229910019093 NaOCl Inorganic materials 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001631457 Cannula Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000252794 Sphinx Species 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003715 calcium chelating agent Substances 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000893712 Bos taurus Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229910015400 FeC13 Inorganic materials 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- OHJKXVLJWUPWQG-PNRHKHKDSA-N Heparinsodiumsalt Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](O)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 OHJKXVLJWUPWQG-PNRHKHKDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 1
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LCQFGWRLFITEFM-UHFFFAOYSA-N OC1=CC=CC=C1Cl.CC(C)C1CCC(C)CC1O.C1CC2(C)C(=O)CC1C2(C)C Chemical compound OC1=CC=CC=C1Cl.CC(C)C1CCC(C)CC1O.C1CC2(C)C(=O)CC1C2(C)C LCQFGWRLFITEFM-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 208000002599 Smear Layer Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001339 alkali metal compounds Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940061631 citric acid acetate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000000001 dental powder Substances 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000001968 dental pulp cell Anatomy 0.000 description 1
- 208000007147 dental pulp necrosis Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000004272 stretch cell Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 210000000332 tooth crown Anatomy 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
Definitions
- the present invention relates to a method for producing a growth factor-loaded biomaterial suitable for use in tissue regeneration, and to a kit for producing a growth factor-loaded biomaterial for use in tissue regeneration.
- the invention is in the field of medical tissue regeneration, in particular in dentistry or bone healing.
- the tooth pulp is enveloped by a hard tooth mantle (enamel, dentin and cementum of the tooth crown and root). Damage to the hard tissue jacket may result in the ingress of bacteria and inflammation of the pulp tissue.
- This makes advanced Stadi ⁇ to usually a root canal treatment is required.
- the pulp tissue is completely removed, whereupon the root canal system is disinfected and sealed with bioinertem synthetic filling material.
- the cleaning and / or disinfection of the root canal system usually takes place by means of aqueous rinsing solutions.
- alternating rinses are carried out with sodium hypochlorite and chlorhexidine solution.
- the rinse solutions may also contain chlorophenol-camphor-menthol, hydrogen peroxide, iodine-potassium iodide, calcium hydroxide, MTAD (a mixture of racyclin, an acid and a surfactant), citric acid or EDTA.
- the rinsing solutions are discarded after use.
- a disadvantage of this root canal treatment is that possibly not irreversibly damaged pulp tissue is completely removed, whereby the pulp function is not maintained.
- the invention is based on the object to provide simple and relatively inexpensive measures or means for dental or bone healing, which support a tissue regeneration, such as a regeneration of the pulp tissue.
- a tissue regeneration such as a regeneration of the pulp tissue.
- the invention has recognized that in hard tissues such as dentin or bone bioactive growth factors are incorporated, which can be solved or released by the treatment with suitable rinsing solutions. This allows that kör ⁇ pereigene growth factors can be incorporated into a biomaterial and used for tissue regeneration.
- the invention is an in-vitro method for producing a growth factor-loaded, for use tissue regeneration suitable biomaterial, comprising the following steps:
- biomaterial refers to biocompatible materials or compositions which can be physiologically tolerated and introduced for long-term retention in an animal or human body, in particular a mammalian body.
- the growth factor-loaded biomaterial contains a framework and growth factors as well as possibly other substances.
- a Ge ⁇ rüstmaterial (engl. Scaffold) forms a three-dimensional porous structure.
- the scaffold material serves both as a carrier for growth factors, and possibly other sub punch ⁇ and secondly tion as a scaffold for Geweberegenera-.
- Frameworks for tissue regeneration are known in the art. In the context of the invention, all known natural or synthetic frameworks for tissue regeneration or combinations of these materials may be used. used. Suitable scaffold materials for the regeneration of tissue are described in Galler KM et al. (2011), Scaffolds for Dental Pulp Tlssue Engineering, Adv Dent Res 23 (3): 333-339.
- the framework material prepared in the context of the method according to the invention can advantageously be selected from the group consisting of synthetic polymers, natural biomaterials, in particular biopolymers and combinations of the abovementioned.
- the framework material is selected from the group consisting of self-assembling peptides (SAP), polyethers, polylactic acid, polyglycolic acid (PGA), copolymers of polylactic acid with polyethers (PLGA), poly-s-caprolactone (PCL), polyurethanes, collagen , Fibrin, polysaccharides and combinations of the foregoing.
- the Ge ⁇ rüstmaterial is selected from the group consisting of self-assembling peptides (SAPs), collagen, fibrin, and combinations of the foregoing.
- self-assembling peptides are very particularly preferred as the framework.
- the growth factor-loaded biomaterial is preferably implantable and / or injectable into a root canal.
- the biomaterial may be liquid or solid or in the form of a gel.
- flowable or biomaterials which can be used by means of a syringe are particularly preferred. These can be injected into a root canal who ⁇ .
- the biomaterial can preferably be applied by cannulas having an inner diameter of less than 2 mm, more preferably less than 1 mm. Preference is furthermore given to a curable, preferably polymerizable, biomaterial which, after introduction into a lesion, for example a root canal, nal, hardens or can be made to harden.
- the biomaterial can harden into a gel in the root canal or is present as a gel.
- the biomaterial can be cured to a gel having a final strength of between 200 and 10000 Pa [G '].
- This self ⁇ properties of the biomaterial can be achieved by choosing a ge ⁇ suitable framework.
- the framework material is preferably implantable in a root canal
- the framework material can preferably be applied by cannulas having an inner diameter of less than 2 mm, more preferably less than 1 mm. Preference is further given a härtba ⁇ res, preferably polymerizable scaffold material that after introduction into a lesion, such as a root canal cures or can be brought to hardening.
- a framework material initially consists of precursors for the cured framework material, in particular monomers, oligomers and polymers.
- the framework material can carry polymerizable or crosslinking groups and be cured via these, wherein the polymerizable or crosslinking groups are not limited to reactive double bonds.
- the polymerization or cross-linking is preferably carried out by electrostatic interactions, in ⁇ play, in self-assembling peptides, or via covalent bonds. It is particularly advantageous if the framework material in the root canal can harden to a gel or is present as a gel.
- the framework material can be made into a gel having a final strength of between 200 and 200 Cure 10000 Pa [G '].
- the Ge ⁇ rüstmaterial comprises at least two components and is curable self-curing (by mixing and reaction of at least two of the encompassed by the framework material components), preferably assumes a gel state.
- hydrogels at ⁇ play as self-assembling peptides or polyether.
- Advantageous polyethers are polyethylene glycols (PEGs).
- PEGs polyethylene glycols
- the polyethers can carry polymerizable or crosslinking groups and cured over them.
- the framework is advantageously in the body depleting ⁇ bar.
- the degradation of the framework material can be controlled.
- the degradation is controlled by the cell. This has the advantage that degradation takes place proportio ⁇ nal to Gewebenu Struktur.
- the framework material is cell adhesive.
- the framework material has adhesive groups to which mediator molecules for growth factors and / or growth factors can preferably be reversibly bound.
- the mediator molecules preferably serve to stabilize and bind the growth factors.
- the framework material has degradable groups in the body.
- groups are by proteinase, e.g. By MMP-2, degradable groups.
- the adhesive and / or body degradable groups are preferably suitable amino acid sequences.
- Growth factors are proteins that promote cell proliferation and differentiation.
- both dentin as well as bone growth are tums tileen incorporated into hard tissue, the bioactive lead ⁇ ben or can be activated.
- the invention has recognized that both hard tissues can thus serve as a reservoir for these growth factors.
- a rinse solution for rinsing of hard tissue is a solution which is provided with human or animal hard tissue, to be brought into contact, for example in the bone or in the tooth, and is capable of releasing ge ⁇ Thematic growth factors in the hard tissue.
- the release can be achieved by demineralization of the hard tissue or its surface layer, for example by pressure-driven ⁇ loading and / or calcium complexation, but preferably carried out by calcium complexation, thus bound in the hard tissue growth factors are exposed.
- the growth factors can also be brought into solution.
- Scope of the invention preferred hard tissue is Zahnhartge ⁇ tissue, particularly dentin. While the dentin at the time of tooth development various growth factors are formed by dentin horrenden cells which are embedded in the dentin matrix and there bioactive lead ⁇ ben or be bioactivated by the inventive method. It is a mixture of growth factors ⁇ .
- the rinse solution for rinsing hard tissue contains at least one demineralizer.
- demineralizer Within the scope of the invention be ⁇ the term Demineralmaschinesstoff draws a means which is adapted in hard tissue, such. B. in dentin or bone, released growth factors bound.
- the demineralization agent should not lead to a de ⁇ naturtechnik the growth factors.
- the at least one preferential Demineralmaschinesstoff is selected from the group consisting of acids, salt ⁇ agents and chelating agents.
- An advantageous salt former is z.
- Other suitable formers of (sparingly soluble) calcium salts may also be used.
- a beneficial acid is citric acid.
- Chelating agents are preferred demineralizing agents in the invention.
- Advantageous chelating agents are selected from the group consisting of EDTA (ethylene diamintetraeesigklare or salts thereof, preferably Alkalime ⁇ metal compounds, especially of sodium), EGTA (ethyl englycol-bis (aminoethyl ether) - ⁇ , ⁇ , ⁇ ', ⁇ ' - tetraacetic acid or its acetates, preferably alkali metal salts, especially of sodium.) and citric acid or citrates, before ⁇ Trains t alkali metal citrates, in particular of sodium. It is advantageous if the rinse solution for rinsing hard tissue has a pH of greater than 4, preferably a pH of greater than 5.
- the rinsing ⁇ solution for washing hard tissue may have a pH value of from 4 to 10, more preferably a pH of 5 to 9, more preferably a pH of 5 to 8, more preferably pH of 6, 5 to 7.5, more preferably have a pH of 7. It should be noted here that when using acids, a pH of> 6 of the rinse solution for rinsing hard tissue is only preferred if the acid is simultaneously a good calcium salt former or calcium chelating agent. To adjust the pH of the rinse solution may contain suitable buffer systems, crizspielswei ⁇ se phosphate buffer (NaH 2 P0 4 / Na2HP04).
- the concentration of the at least one demineralizing agent in the rinse solution for rinsing hard tissue at least 5 wt .-%, more preferably at least 10 wt .-%, more preferably 10 wt .-% to 20 wt. %, more preferred
- the rinsing solution for rinsing hard tissue as a chelating agent contains EDTA (ethylenediaminetetraacetic acid or ethylenediamine tetraacetate).
- EDTA ethylenediaminetetraacetic acid or ethylenediamine tetraacetate
- it is at the Spüllö ⁇ solution for washing hard tissue is an aqueous EDTA solution.
- EDTA solutions are used in endodontics, where they are used, for example, to remove a
- the manufacturing process of the invention provides for the Be ⁇ riding position of a sample taken an animal or human body rinse solution for hard tissue.
- This is a rinsing solution which, over a certain period of time, is treated with animal or human hard tissue, eg. As bone or tooth hard tissue was in contact.
- the rinsing solution contains at least one Demineraltechnischsstoff for Hartge's ⁇ weave and a product obtained by contact of the rinse solution with the hard tissue from the hard tissue growth factor mixture.
- the at least one of the extracted Demineralmaschinesstoff in an animal or human body washing solution is an above-described Deminera ⁇ lmaschinesstoff. It may advantageously be selected from the group consisting of acids, salt formers and chelating agents.
- the at least one Deminera ⁇ l Deutschensstoff is preferably selected from the group consisting of EDTA (Ethylendiamintetraeesigklare or ethylenediaminetetraacetate), EGTA (ethylene glycol bis (aminoethyl ether) -N, ⁇ ', N' tetraacetic acid and ethyl englycol bis (aminoethyl ether) - ⁇ , ⁇ , ⁇ ', N'tetraacetat) and citric acid or citrate.
- Particularly preferred Deminerali ⁇ stechniksstoff are citric acid and citrate, and EDTA.
- the growth factor mixture in the rinsing solution taken from an animal or human body generally contains all the growth factors occurring in the hard tissue, the ratio of the growth factors to one another in the tissue Rinse solution corresponds to the natural ratio of growth factors in the hard tissue.
- the rinsing solution taken from an animal or human body has growth factors whose concentration in the rinsing solution is particularly preferably between 0.0001 ng / ml and 1000 ng / ml, preferably between 0.0001 ng / ml and 100 ng / ml between 0.0001 ng / ml and 50 ng / ml, most preferably between 0.001 ng / ml and 10 ng / ml.
- the rinsing solution taken from an animal or human body contains at least 0.01 ng / ml of a transforming growth factor (TGF), preferably at least 0.05 ng / ml TGF, more preferably at least 0.1 ng / ml TGF, most preferably at least 0.3 ng / ml TGF.
- TGF transforming growth factor
- taken from a human or animal body flushing solution is between 0.01 ng / ml and 500 ng / ml contains preference between 0.01 ng / ml and 100 ng / ml, particularly before ⁇ Trains t between 0, 1 ng / ml and 50 ng / ml, most preferably between 0.1 ng / ml and 10 ng / ml TGF.
- a preferred transforming growth factor is TGF-beta growth factor (TGF- ⁇ ).
- TGF- ⁇ TGF-beta growth factor
- a particularly preferred transforming growth factor is the transforming one
- TGF-ß-1 Growth factor beta-1
- the rinse solution taken from an animal or human body contains at least 0.0001 ng / ml vascular endothelial growth factor (VEGF), preferably at least 0.001 ng / ml VEGF.
- VEGF vascular endothelial growth factor
- taken from a human or animal body rinse solution contains between 0.0001 ng / ml and 5 ng / ml VEGF, preferably between 0.0001 ng / ml and 10 ng / ml VEGF, more preferably between 0.001 ng / ml and 1 ng / ml VEGF, most preferably between 0.001 ng / ml and 0, 1 ng / ml VEGF.
- the rinse solution taken from an animal or human body contains at least 0.0001 ng / ml fibroblast growth factor (FGF), preferably at least 0.001 ng / ml FGF.
- FGF fibroblast growth factor
- the rinsing solution taken from an animal or human body contains between 0.0001 ng / ml and 5 ng / ml FGF, preferably between 0.0001 ng / ml and 10 ng / ml FGF, more preferably between 0.001 ng / ml and 1 ng / ml FGF, most preferably between 0.001 ng / ml and 0.1 ng / ml FGF.
- a preferred fibroblast growth factor is fibroblast growth factor 2 (FGF-2).
- the rinsing solution taken from an animal or human body contains between 0.0001 ng / ml and 100 ng / ml, preferably between 0.0001 ng / ml and 10 ng / ml, more preferably between 0.001 ng / ml and 1 ng / ml, most preferably ng / ml of a growth factor which is selected from ⁇ from the group consisting of the weave is between 0.001 ng / ml and 0.1 in Zahnhartge- occurring and bone growth factors.
- the rinsing solution taken from an animal or human body contains between 0.0001 ng / ml and 100 ng / ml, preferably between 0.0001 ng / ml and 10 ng / ml, more preferably between 0.001 ng / ml and 1 ng / ml, most preferably between 0.001 ng / ml and 0.1 ng / ml egg ⁇ nes growth factor is selected from the group sawn standing from platelet-associated growth factors
- PDGF bone morphogenetic growth factors
- IGF insulin-like growth factors
- EGF epidermal growth factors
- the rinsing solution taken from an animal or human body preferably has a pH of greater than 4, particularly preferably greater than 5.
- Advantageous pH values for the extracted an animal or human body washing solution is between 4 and 10, preferably between 5 and 9, more preferably between 5 and 8, more preferably between 6.5 and 7.5, very particularly before Trains t ⁇ at a pH of 7.
- the framework material is loaded with at least ei ⁇ nem growth factor.
- the loading of the framework material is carried out according to the invention by contacting the rinsing solution taken from an animal or human body with the framework material.
- the contacting may include the application or introduction of the rinse solution onto or into the framework material.
- the loading of the framework material takes place by mixing the rinse solution with the framework material.
- a dispersion or solution by mixing framework material and rinse solution is prepared.
- the framework material is loaded with at least one naturally occurring growth factor in bone or tooth hard tissue.
- the at least one growth factor from ⁇ is preferably selected from the group consisting of transforming growth factors (TGF), vascular endothelial growth Factors (VEGF), fibroblast growth factors (FGF), platelet-associated growth factors (PDGF), bone morphogenetic growth factors (BMP), insulin-like growth factors (IGF) and epidermal growth factors (EGF).
- TGF transforming growth factors
- VEGF vascular endothelial growth Factors
- FGF fibroblast growth factors
- PDGF platelet-associated growth factors
- BMP bone morphogenetic growth factors
- IGF insulin-like growth factors
- EGF epidermal growth factors
- BMP-2 bone morphogenetic growth factor 2
- the scaffold is preferably with the at least one material growth in amounts between 0.0001 ⁇ Factor ng / mL and 100 ng / ml, preferably upstream from 0.0001 ng / ml and 10 ng / ml, particularly be ⁇ 0.001 ng between vorzugt / ml and 1 ng / ml, most preferably loaded between 0.001 ng / ml and 0.1 ng / ml.
- the framework material is loaded with a growth factor mixture.
- the growth factor mixture contains at least two growth factor components.
- At least one growth factor component is preferably of the at least two equipsmidpo ⁇ components a trans- formiere growth factor (TGF), wherein the transforming growth factor TGF-beta-growth factor (TGF-ß) is especially preferred and wherein the transforming growth factor-beta-1 ( TGF- ⁇ -1) is very particularly preferred.
- TGF trans- formiere growth factor
- TGF-ß transforming growth factor-beta-growth factor
- TGF- ⁇ -1 TGF- ⁇ -1
- the framework material with at least 0.01 ng / ml TGF, preferably at least 0.05 ng / ml TGF, more preferably at least 0.1 ng / ml TGF especially be ⁇ vorzugt at least 0.3 ng / ml TGF loaded.
- the framework material with a quantity of TGF between 0.01 ng / ml and 500 ng / ml, vorzugswei- se is between 0.01 ng / ml and 100 ng / ml, more preferably between 0.1 ng / ml and 50 ng / ml, most preferably between 0.1 ng / ml and 10 ng / ml loaded.
- at least one growth factor is preferably selected from the group consisting of vascular endothelial growth factors (VEGF) and fibroblast growth factors (FGF).
- VEGF vascular endothelial growth factors
- FGF fibroblast growth factor 2
- FGF-2 fibroblast growth factor 2
- the framework material is loaded with at least 0.0001 ng / ml VEGF, preferably at least 0.001 ng / ml VEGF.
- the framework material with an amount of VEGF is between 0.0001 ng / ml and 5 ng / ml, preferably between 0.0001 ng / ml and 10 ng / ml, more preferably between 0.001 ng / ml and 1 ng / ml. ml, most preferably loaded between 0.001 ng / ml and 0.1 ng / ml.
- the framework material is loaded with at least 0.0001 ng / ml FGF, preferably at least 0.001 ng / ml FGF.
- the framework material with an amount of FGF is between 0.0001 ng / ml and 5 ng / ml, preferably between 0.0001 ng / ml and 10 ng / ml, more preferably between 0.001 ng / ml and 1 ng / ml. ml, most preferably loaded between 0.001 ng / ml and 0.1 ng / ml.
- the growth factor components with which the skeleton material is loaded the growth factor mixture corresponding to the growth factor components in the growth factor mixture of the extracted an animal or human body washing solution, that the framework material is loaded with all growth ⁇ factor components that are found in the rinse solution.
- the rinsing solution in step c) is brought in an amount on the scaffold ⁇ material which enables loading of the scaffold with a growth factor mixture in the size range of the concentration in the rinse solution, or even larger.
- the immobilization of the growth factors in or on the biomaterial or framework material preferably takes place via weak, non-covalent bonds, so that it is reversible.
- the binding can be via mediator molecules, such as heparin.
- the rinsing solution taken from an animal or human body is prepared for use with the framework material before the skeleton material is loaded.
- the conditioning of the rinse solution includes any steps that require the use of the rinse solution in a biomaterial.
- the treatment of the rinse solution may include the sterilization of the rinse solution and / or the inactivation of toxins in the rinse solution and / or the removal of toxins from the rinse solution and / or the addition of one or more adjuvants to the rinse solution.
- the treatment of the rinsing solution taken from an animal or human body preferably comprises the addition of at least one pharmaceutically active substance and / or the addition of at least one mediator for stabilizing and binding growth factors.
- the pharmaceutically active substance is preferably an antibiotic.
- the term intermediary refers to chemical substances or molecules, in particular special biopolymers, which causes the binding of at least one growth factor to the framework material or under ⁇ supported.
- a preferred mediator is heparin. Heparin is a sulfated and thus negatively charged glycosaminoglycan, which occurs naturally in the extracellular matrix and can bind certain growth factors (heparin-binding growth factors) and protect against proteolytic degradation. This effect can be imitated in synthetic matrices.
- An advantage of treating the rinsing solution with heparin is that the heparin-binding growth factors released from the dentin can be bound to the framework via heparin and thus their half-life can be extended.
- Rinsing solution removed from the body may include the removal of demineralizing agent from the rinse solution.
- the at least one demineralizing agent is EDTA and the treatment of the rinse solution comprises the degradation of EDTA and / or the partial or complete removal of EDTA and / or its degradation products from the rinse solution. Removal of EDTA from the rinse solution may involve recomplexing of EDTA and removal and / or degradation of the EDTA complex.
- the EDTA may preferably be through the
- the treatment may therefore include the degradation of EDTA with addition of iron (III) salts and / or by irradiation with UV light.
- the irradiation with UV light preferably takes place in the wave length range above 200 nm.
- the preparation of the rinse solution advantageously teilwei ⁇ se or complete removal of EDTA from the rinsing solution and / or nenleyerharzpizer of its degradation products using suitable anion may, for example, bonded by means of quaternary ammonium ⁇ groups to suitable carrier polymers For example, crosslinked agarose gels.
- suitable carrier polymers For example, crosslinked agarose gels.
- a preferred hard tissue in the context of the invention is hard dental tissue, in particular dentin.
- the growth factor-loaded biomaterial may contain autologous or allogeneic stem cells. In a preferred embodiment, the growth factor-loaded biomaterial contains autologous stem cells. In another preferred
- Embodiment contains the growth factor-loaded Bioma ⁇ material no stem cells.
- the invention also contemplates growth factor-loaded biologic material for use in tissue regeneration, which is obtainable by the method described above.
- the invention provides a biomaterial loaded with a growth factor mixture comprising at least two naturally occurring growth factors in the dentin for use in the pulp tissue regeneration, which is characterized in that the weight ratio of the wax Factors in the biomaterial with the natural weight ratio of the growth factors to each other in the dentin is correlated.
- the at least two na ⁇ Moslich occurring in the dentine growth factors selected from the group consisting of transforming growth ⁇ factors (TGF), are vascular endothelial growth factors
- VEGF fibroblast growth factors
- FGF fibroblast growth factors
- PDGF platelet-associated growth factors
- BMP bone morphogenetic growth factors
- IGF insulin-like growth factors
- bone morphogenetic growth factor 2 BMP-2
- BMP-2 bone morphogenetic growth factor 2
- the biomaterial may be loaded with a growth factor mixture of all growth factors naturally occurring in the dentin.
- a corresponding biomaterial can be obtained by the above described driving Ver ⁇ . The correlation of the weight ratio of the growth factors to each other in the biomaterial with the natural weight ratio of the profundsfakto ⁇ ren one another in the dentine is then obtained by the production method.
- the rinsing solution or the absolute concentration and / or the ratio of the ratios of the growth factors in the dentin to one another can be imitated in the biomaterial.
- the growth factors used for this purpose can originate from humans or animals or be genetically engineered.
- the biomaterial preferably contains at least one transforming growth factor (TGF), in particular TGF- ⁇ -1, in an amount between TGF- ⁇ -1 and TGF- ⁇ -1.
- TGF trans ⁇ transforming growth factor
- VEGF vascular endothelial growth factor
- TGF: FGF FGF is 2: 1 to
- TGF FGF equal to 2: 1 to 50: 1 or 2: 1 to 20: 1.
- the invention also relates to a kit for producing a growth factor-loaded biomaterial for use in tissue regeneration.
- the kit according to the invention comprises a) framework material and b) a rinsing solution for rinsing human or animal hard tissue which contains at least one hard tissue degradation agent.
- suitable framework materials have already been described in the context of the manufacturer ⁇ development method according to the invention. These explanations are referred to.
- the framework materials described therein can also be used in the context of the kit according to the invention as component a).
- the framework material is selected from the group consisting of synthetic poly mers ⁇ , natural biomaterials, in particular polymers and combinations of the foregoing; wherein the framework material is preferably selected from the group consisting of self-organizing peptides (SAP), polyethers, polylactic acid, polyglycolic acid (PGA), copolymers of polylactic acid with polyethers (PLGA), poly-s-caprolactone (PCL), polyurethanes, Collagen, fibrin, polysaccharides and combinations of the foregoing; wherein the framework is more preferably selected from the group consisting of self-assembling peptides (SAP), collagen, fibrin, and combinations of the foregoing.
- SAP self-organizing peptides
- PGA polyglycolic acid
- PCL poly-s-caprolactone
- the framework is more preferably selected from the group consisting of self-assembling peptides (SAP), collagen, fibrin, and combinations of the foregoing.
- the framework material has adhesive groups may be reversibly bound to the mediator molecules for wax ⁇ tums tinten and / or growth factors and / or it has degradable groups in the body.
- the adhesive and / or degradable groups are preferably amino acid sequences.
- the rinse solution (component b) is intended to be contacted with tie ⁇ hari whatsoeverm or human hard tissue, such as bone or teeth in contact.
- tie ⁇ hari symbolizem or human hard tissue such as bone or teeth in contact.
- inventive production process have been for fiction, ⁇ proper kit suitable irrigation solutions for rinsing of human or animal hard tissue or appropriate in the context Demineraltechnischsstoff described. On these explanations are referred to.
- the beschrie there ⁇ surrounded irrigation solutions for rinsing of human or animal hard tissue can also be used as part of the invention shown SEN kits as component b).
- component b) of the kit may be a ready-to-use rinse solution for rinsing human or animal hard tissue.
- a ready-to-use rinse solution already contains the at least one demineralizing agent in a ready-to-use concentration. This has the advantage that the solution before use with the hard tissue z. B. no longer needs to be diluted extra.
- the concentra ⁇ on the at least one Demineraltechnischsstoffs in the rinse solution for rinsing of hard tissue at least 5 wt .-%, more preferably 10 wt .-% of at least further preference ⁇ , 10 wt .-% to 20 wt .-%, particularly preferably from 10% to 17% by weight, most preferably 17% by weight.
- Wash hard tissue may advantageously a pH of greater than 4, preferably a pH of greater than 5, white ⁇ ter preferably has a pH value of 4 to 10, further before ⁇ preferably a pH of 5 to 9, more preferably have a pH of 5 to 8, more preferably a pH of 6.5 to 7.5, particularly preferably a pH of 7.
- the at least one demineralization agent is selected from the group consisting of
- Acids, salt and chelating agents wherein the at least one demineralizing agent is preferably selected from the group consisting of EDTA (ethylenediaminetetraacetic acid or ethylenediaminetetraacetate), EGTA (ethylene glycol bis (aminoethyl ether) -N, ⁇ ', N'-tetraacetic acid or ethyleneglycol bis (aminoethyl ether) - ⁇ , ⁇ , ⁇ ', N'tetraacetate) and citric acid / citrate ,
- EDTA ethylenediaminetetraacetic acid or ethylenediaminetetraacetate
- EGTA ethylene glycol bis (aminoethyl ether) -N, ⁇ ', N'-tetraacetic acid or ethyleneglycol bis (aminoethyl ether) - ⁇ , ⁇ , ⁇ ', N'tetraacetate
- citric acid / citrate
- the component b) of the kit can preferably be an aqueous solution of a calcium chelating agent.
- the at least one Demineraltechnischsstoff lemons ⁇ acid or citrate and the rinsing solution for rinsing of hard tissue has a pH value of greater than 4, preferably a pH of 5 to 7, more preferably from 4.5 up to 6.5.
- the at least one demineralization agent is EDTA and the rinsing solution for rinsing hard tissue has a pH of at least 6, preferably a pH of at least 7, more preferably a pH of 7 to 9 on.
- a kit of the invention may advantageously further comprise at least one component that is selected to support from the group consisting of means for the removal of EDTA from a solution promoters, which effect the binding of at least one growth factor to the biomaterial, insbesonde ⁇ re of the framework material or and ei ⁇ ner device for applying the rinse solution.
- the means for removing EDTA from a solution may preferably comprise ferric salts and / or anion exchange resins.
- a preferred mediator is heparin.
- the device for application of the rinsing solution preferably comprises a syringe and a cannula, particularly preferably a blunt endo-cannula.
- a preferred hard tissue in the context of the invention is hard dental tissue, in particular dentin.
- the method of treatment comprises the steps of: a) providing a rinse solution for rinsing human or animal hard tissue containing at least one hard tissue demineralizer selected from the group consisting of acids, calcium salt and calcium chelators; b) contacting the hard tissue with the rinse solution to rinse human or animal hard tissue under conditions allowing release of growth factors bound in hard tissue; c) removal of growth factor enriched
- Rinsing solution from the animal or human body d) preparing a growth factor-loaded biomaterial, according to the in-vitro method of the invention described above, using the growth factor-enriched rinse solution of step c); e) introducing the growth factor-loaded biomaterial into an animal or human body.
- hard tissue is hard dental tissue, in particular dentin.
- the hard tissue may also be bone tissue.
- t is human hard tissue.
- Preference ⁇ example is introduced in step e) the growth factor-laden Bioma ⁇ TERIAL in the body, with the hard tissue, the rinsing solution was contacted for washing the human or animal hard tissue in step b), ie the Bioma ⁇ TERIAL in view of the human or animal Body in which it is introduced an autologous bioma ⁇ material.
- the introduction of autologous biomaterials is preferred because no immune response is expected.
- the Bioma ⁇ TERIAL may contain autologous or allogeneic stem cells.
- the biomaterial contains autologous stem cells.
- the biomaterial does not contain stem cells.
- suitable irrigation solutions for rinsing of human or animal hard tissue or suitable Demineralmaschinesstoff be ⁇ already or the kit of the invention have been described in the context of the invention Heinrichsverfah- proceedings. These explanations are referred to.
- the rinsing solutions described there for rinsing human or animal hard tissue can also be used in the treatment method described above.
- ⁇ 6 more preferably at least 10 wt .-%, more preferably 10 wt .-% to 20 wt .-%, particularly preferably 10 wt .-% to 17 wt .-%, most preferably 17 wt .-% is ,
- the at least one demineralizing agent is selected from the group consisting of EDTA (ethylenediaminetetraacetic acid or ethylenediaminetetraacetate), EGTA (ethylene glycol bis (aminoethyl ether) - ⁇ , ⁇ , ⁇ ', ⁇ '-tetraacetic acid and ethylene glycol bis ( aminoethyl ether) - N, N, ⁇ ', N' tetraacetate) and citric acid / citrate.
- the rinse solution contains Rinsing of hard tissue from step a) as a demineralizing EDTA (eg disodium salt).
- the rinse solution is an aqueous EDTA solution.
- the concentration of EDTA is preferably in the rinse solution for rinsing of human or animal hard tissue, at least 5 wt .-%, more preferably Minim ⁇ least 10 wt .-%, more preferably 10 wt .-% to 17 wt, -%, more preferably at least 15 wt .-%, particularly preferably ⁇ 17 wt .-%.
- the contacting of the hard tissue with rinsing solution for rinsing of human or animal hard tissue in step b) can be carried out, for example, using a syringe system.
- the syringe system preferably comprises a blunt endocannula.
- the exposure time to the rinse solution is the hard tissue in step b) is between 0.1 min and 30 min, before ⁇ preferably between 1 min and 30 min, more preferably between 1 min and 20 min, more preferably between 2 min and 15 min, more preferably between 5 min and 20 min, most preferably between 5 min and 15 min.
- a sonic or ultrasound-assisted activation of the rinse solution can take place.
- step c) can take place, for example, by means of a syringe system.
- the syringe system preferably comprises a blunt endocannula.
- Step d) relates to the dung OF INVENTION ⁇ modern manufacturing method of a loaded with at least one growth factor with the biomaterial bathga ⁇ be already above described, that the rinse solution from step c is used).
- the preparation process according to the invention has already been described above. Reference is made to these explanations.
- the growth factor-laden Bioma TERIAL at least one na ⁇ Moslich occurring in bone or tooth tissue growth factor.
- at least one growth factor is selected from the group consisting of transforming growth factors (TGF), vascular endothelial growth factors (VEGF), fibroblast growth factors (FGF), platelet-associated growth factors (PDGF), bone morphogenetic growth factors (BMP), insulin-like growth factors ( IGF) and epidermal growth factors (EGF).
- TGF transforming growth factors
- VEGF vascular endothelial growth factors
- FGF fibroblast growth factors
- PDGF platelet-associated growth factors
- BMP bone morphogenetic growth factors
- IGF insulin-like growth factors
- EGF epidermal growth factors
- BMP-2 bone morphogenetic growth factor 2
- the bio ⁇ material contains the at least one growth factor in amounts between 0.0001 ng / ml and 500 ng / ml, preferably between 0.0001 ng / ml and 100 ng / ml, more preferably between 0.0001 ng / ml and 10 ng / ml, more preferably between 0.001 ng / ml and 1 ng / ml, most preferably between 0.001 ng / ml and 0.1 ng / ml.
- the biomaterial contains a growth factor mixture containing at least two growth factors.
- At least one growth factor is preferably of the at least two growth factors transforming wax tums tile (TGF), particularly preferably the transformie ⁇ Rende growth factor a TGF-beta-growth factor (TGF-ß) is very particularly preferably the transforming equipsfak tor beta-1 (TGF- ⁇ -1).
- TGF transforming wax tums contouring
- TGF-ß transformie ⁇ Rende growth factor
- TGF-ß TGF-beta-growth factor
- TGF-ß the transformie ⁇ Rende growth factor a TGF-beta-growth factor
- TGF-ß the transformie ⁇ Rende growth factor a TGF-beta-growth factor
- TGF-ß the transformie ⁇ Rende growth factor a TGF-beta-growth factor
- TGF-ß the transformie ⁇ Rende growth factor a TGF-beta-growth factor
- TGF-ß the transforming equipsfak tor beta-1
- the loaded biomaterial contains between 0.01 ng / ml and 500 ng / ml, preferably between 0.01 ng / ml and 100 ng / ml, more preferably between 0.1 ng / ml and 50 ng / ml, most preferably between 0.1 ng / ml and 10 ng / ml TGF.
- At least one growth factor is preferably selected from the group of vascular endothelial growth factors (VEGF) and fibroblast growth factors (FGF), particularly preferably the fibroblasts are growth factors of the fibroblasts
- VEGF vascular endothelial growth factors
- FGF fibroblast growth factors
- the loaded biomaterial at least 0.0001 ng / ml VEGF, preferably ⁇ example at least 0.001 ng / ml VEGF.
- the loaded biomaterial contains at least 0.0001 ng / ml FGF, preferably at least 0.001 ng / ml FGF.
- the biomaterial loaded from 0.0001 ng / ml and 5 ng / ml, more preferably between 0.0001 ng / ml and 10 ng / ml, more preferably Zvi ⁇ rule 0.001 ng / ml and 1 ng / ml, very particularly preferably between 0.001 ng / ml and 0.1 ng / ml FGF.
- the loaded biomaterial preferably contains more wax ⁇ tums tinten. These are preferably more occurring in the tooth ⁇ tissue and / or bone growth factors.
- The- Other growth factors may preferably be selected from the group consisting of platelet-associated growth factors (PDGF), bone morphogenetic growth factors (BMP), insulin-like growth factors (IGF), epidermal growth factors (EGF).
- PDGF platelet-associated growth factors
- BMP bone morphogenetic growth factors
- IGF insulin-like growth factors
- EGF epidermal growth factors
- a preferred bone morphogenetic growth factor is bone morphogenetic growth factor 2 (BMP-2).
- the loaded biomaterial contains between 0.0001 ng / ml and 500 ng / ml, preferably between 0.0001 ng / ml and 100 ng / ml, preferably between 0.0001 ng / ml and 10 ng / ml between, more preferably between 0.001 ng / ml and 1 ng / ml, more preferably between 0.001 ng / ml and 0.1 ng / ml of a growth factor occurring in the tooth hard tissue and / or bone.
- the loaded biomaterial contains between 0.0001 ng / ml and 100 ng / ml, preferably between 0.0001 ng / ml and 10 ng / ml, more preferably between 0.001 ng / ml and 1 ng / ml, more preferably between 0.001 ng and 0.1 ng / ml of a growth factor selected from the group consisting of platelet-associated growth factors (PDGF), bone morphogenetic growth factors (BMP), insulin-like growth factors (IGF), epidermal cells
- PDGF platelet-associated growth factors
- BMP bone morphogenetic growth factors
- IGF insulin-like growth factors
- EGF Growth Factors
- the growth factor components of the growth factor mixture with which the biomaterial is loaded correspond to the growth factor components in the growth factor mixture of the rinse solution from step c), ie the biomaterial is loaded with all growth factor components which are present in the rinsing solution from step c) taken from the animal or human body ) Find.
- the biomaterial may be liquid or solid or in the form of a gel. It may be any biomaterial already described above in the context of the production process according to the invention.
- the biomaterial or the suspension or solution of the (loaded) framework material can be ⁇ suspension or solvent or other components removed partially or completely. It can also be added to further compo ⁇ nents.
- the biomaterial can be partially or completely hardened before or after introduction into a root canal.
- the biomaterial is hardened or hardened in the root canal. Preferably, it ⁇ following hardening by polymerization.
- the invention allows an improved method for root canal treatment, comprising the following steps:
- Root canal preparation wherein a) tissue disorders with prior partial removal of the Pulpage- (Step 2 a) takes place a slight Extension C ⁇ tion of the root canal to allow the Desin Stammi ⁇ one; b) pagewebes by prior complete removal of the powder diffractometer (step 2b) is carried out an expansion of the Wur ⁇ zelkanals, wherein the apex (apex) is extended to at least 0.8 mm to the A ⁇ growth of cells for regeneration and Blutge- to promote cask sprouting;
- Desin ⁇ fection is done, for example, chlorhexidine, sodium hypochlorite;
- the rinse solution for rinsing human or animal hard tissue containing at least one demineralizer selected from group best ⁇ starting from acids, salt and / or chelating agents;
- Removal of the at least one growth factor is ⁇ enriched rinse solution from the body
- step 2 If in step 2 is effected a complete removal of the powder-pagewebes, it is advantageous between the crotch ⁇ th 4 and 5 for a period of 1 to 2 weeks a me- dikamentinate insert into the root canal to introduce.
- step 4 is derholt before starting from step 5 as ⁇ .
- the drug insert may be selected from the group consisting of calcium hydroxide pastes, antibiotic corticosteroid preparations and antibiotic mixtures.
- Rinsing solutions suitable for the method of root canal treatment for rinsing human or animal hard tissue or suitable demineralizing agents have already been described in the context of the preparation method or the kit according to the invention. These explanations are referred to.
- the rinsing solutions described therein for rinsing human or animal hard tissue can also be used in the above-described method for root canal treatment.
- the rinsing solution for rinsing human or animal hard tissue has a pH of greater than 4, preferably a pH greater than 5, more preferably a pH of from 4 to 10, more preferably a pH of from 5 to 9, more preferably a pH of 6 to 8, more preferably a pH of 6.5 to 7.5, most preferably a pH of 7.
- the concentration of the at least one Demineral Deutschensstoffs in the rinse solution to the SPC ⁇ len of hard tissue at least 5 wt .-%, more preferably least 10 wt .-%, more preferably 10 wt .-% to 20 wt .-%, more preferably 10 wt .-% to 17 wt .-%, most preferably 17 wt .-% is.
- At least one demineralizing agent is selected from the group consisting of EDTA (ethylenediaminetetraacetic acid or ethylenediaminetetraacetate), EGTA (ethylene glycol bis (aminoethyl ether) - ⁇ , ⁇ , ⁇ ', ⁇ '-tetraacetic acid or ethylene glycol bis (aminoethyl ether) N, N, ⁇ ', N' tetraacetate) and citric acid or citrate.
- EDTA ethylenediaminetetraacetic acid or ethylenediaminetetraacetate
- EGTA ethylene glycol bis (aminoethyl ether) - ⁇ , ⁇ , ⁇ ', ⁇ '-tetraacetic acid or ethylene glycol bis (aminoethyl ether) N, N, ⁇ ', N' tetraacetate
- citric acid or citrate In a preferred method corresponds to the root canal treatment keeps the rinse solution
- the concentration of EDTA in the rinse solution for rinsing human or animal hard tissue is at least 5 wt%, more preferably at least 10 wt%, more preferably 10 wt% to 17 wt%, more preferably at least 15 Wt .-%, particularly preferably 17 wt .-%.
- a particularly preferred rinse solution for rinsing hard tissue in the context of the method is a 10% (w / w) to 17% (w / w) aqueous EDTA solution having a pH of 7.
- the contacting of the dentin with the rinse solution for rinsing human or animal hard tissue in step 5 can be done, for example, using a syringe system.
- the syringe system preferably comprises a luer lock syringe and / or a blunt endocannula.
- Advantageous ingly is the exposure time to the rinse solution to the dentin in step 5 is between 0.1 min and 30 min, preferably ⁇ between 1 min and 30 min, more preferably between 1 min and 20 min, more preferably between 2 min and 15 min, especially preferably between 5 minutes and 20 minutes, most preferably between 5 minutes and 15 minutes.
- the removal in step 6) can take place, for example, by means of a syringe system.
- the syringe system preferably comprises Luer-Lock syringe and / or a blunt endocannula.
- the biomaterial may be covered with a suitable material, such as MTA (mineral trioxide aggregate), and the root canal sealed with bacteria by laying a conventional filling.
- a suitable material such as MTA (mineral trioxide aggregate)
- MTA mineral trioxide aggregate
- Fig. 1 Data for the release of the growth factor TGFßl of dentine in response to the pH of the rinse solution ⁇ ,
- FIG. 2 shows data for the release of the growth factor TGFßl of dentine in response to the type of pretreatment ⁇ lung
- Fig. 3 Data for the release of the growth factor VEGF of dentine in response to the type of pretreatment ⁇ lung
- Fig. 4 cell vitality of dental pulp stem cells in one
- FIG. 5 Release of the growth factors from a biomaterial
- FIG. 6 Cell numbers of dental pulp stem cells in growth factor-loaded biomaterial
- Fig. 7 Tissue formation in Dentinzylindern after
- the thickness of hole saw dentine slices were 200 ym and diam ⁇ sers 8 mm prepared and stored up to the beginning of the experiment in 10 ⁇ 6iger chloramine solution from extracted teeth using an inside.
- the disks were washed with phosphate buffered saline (1x PBS, pH 7) and each disk was placed in the well of a 48-well plate. As a result, each slice was filled with 100 ⁇ one
- Rinse solution aqueous EDTA solution 10% or 0.268 M, pH 6 or pH 7, prepared with EDTA disodium salt dihydrate, Appellant No. A3234
- ELISA Enzyme-linked immunosorbent assay
- aqueous EDTA rinse solution (10% or 0.268 M, pH 7) was contacted with dentine by the procedure of Example 1.
- Figure 2 compares the concentration of TGF ⁇ 1 in the rinse solution after a rinse solution exposure time to the dentin of 5 minutes, 10 minutes, and 20 minutes, respectively, in the case where the dentin was used to rinse hard tissue prior to application of the EDTA-containing solution Procedure in Example 1 with sodium hypochlorite (NaOCl, 5.25%) or
- Chlorhexidine (chlorhexidine digluconate, 0.12%) was pretreated for 5 min or 10 min or the EDTA-containing Solution for rinsing hard tissue without pretreatment of the dentin with chlorhexidine or sodium hypochlorite was applied.
- TGF ⁇ 1 is released from the dentin when the rinse solution containing EDTA is used. It shows a time-dependent effect, with longer exposure time of EDTA more TGFßl is released. If disinfectant chlorhexidine is used before EDTA, this effect is slightly increased with an exposure time of chlorhexidine of 5 min. Rinsing with sodium hypochlorite before EDTA application reduces the profunda period of EDTA.
- FIG. 3 shows higher growth factor concentrations in the case of previous use of chlorhexidine than with NaOCl.
- An EDTA rinse solution according to Example 1 was admixed with iron (III) chloride and irradiated with UV light at 254 nm (mains handlamp UVA / C (No. 862 506), Dr. Göbel UV-Elektronik GmbH).
- the residual content of EDTA in the rinse solution was less than 5% of the rinse solution used, determined by means of HPLC (Waters 2695 Separations Module and Waters 2998 Photo ⁇ diode Array Detector with HPLC column Nucleodur Sphinx RP 5 ym (CC250 / 4)).
- starting component A is a solution of a part of self-organizing peptides (Sequences 1) in a designated, multi-chamber syringe system.
- the rinse solution is removed from the root canal, the EDTA is removed from the solution using methods described in Example 4 and / or 5, this is mixed with the heparin / PBS solution.
- the growth factors in solution are bound and stabilized by the heparin.
- this solution is mixed with the second part of the self-assembling peptides (pendant sequences) and with the starting component A and injected into the root canal. Within 3-5 minutes, gelation occurs, which is induced in this material by electrostatic interaction between the two peptide sequences.
- the PBS solution a phosphate-buffered saline solution (lx PBS, pH 7), is introduced into the channel, pipetted up and down and finally removed from the channel. To this solution was added, followed by heparin ⁇ ver mixed with the powdered framework material.
- a stock solution of peptide in lxPBS of 2% by weight was prepared.
- the respective growth factor was dissolved in a heparin / PBS solution.
- both components were mixed and wells pipetted into a 96-well plate, mixing induces gelation.
- the volume per gel was 100 yL, the final concentration of peptide 1 wt-6, heparin 1 mg / ml, and growth factor 100 ng per gel.
- gels without heparin were prepared and the samples were prepared in triplicates. Each gel was now with
- dental pulp stem cells are sown in a monolayer in 24-well plates, the cell density was 2.5 ⁇ 10 3 cells per well. The cells remained untreated for 24 hours, during which time cell adhesion occurred.
- An insert was then placed in each well containing a heparin and growth factor enriched peptide hydrogel. The volume per gel in the insert was 25 yl, the amount of growth factor for TGF ⁇ 1 was 25 ng, for FGF-2 100ng.
- the gels in the inserts were overlayed with cell culture medium, allowing continuous delivery of growth factor into the medium over the 14 day trial period.
- control groups no gels have been used in the insert, but the growth factors were added to the cell culture medium was changed every 2 days, whereby a renewed supply of growth factor was ⁇ .
- 3 experimental groups (1: cells and gels in inserts without growth factor, 2: gels in inserts with 25ng TGF ⁇ 1 and 3: gels in inserts with 100ng of FGF-2).
- 3 control groups (1: cells without gels, normal cell culture medium, 2: cells without gels, cell culture medium with 2.5 ng TGF ⁇ 1, 3: cells without gels, cell culture medium with 10 ng FGF-2).
- the cell morphology was photographically documented after 3 and 14 days. Cell growth was determined after 3, 7 and 14 days by counting in a Neubauer counting chamber.
- TGF-1 treated Zel ⁇ len showed an increase in the cell body and cluster formation after 14 days, while the proliferation was slowed.
- FGF-2 induced a spindle-shaped cell type with increased proliferation rate.
- the described experiment demonstrates that TGF ⁇ 1 as well as FGF-2 retain their bioactivity upon incorporation and subsequent release from hydrogels.
- Biomaterial loaded with growth factors is introduced into the root canal by means of a syringe system.
- the gel in the root canal serves as a guide for regeneration, it should be attracted by the recirculated growth factors cells and brought in the gel for proliferation, differentiation and tissue formation. Furthermore, growth factors are also exposed to the dentin surface after EDTA pretreatment. For this purpose, experiments were imitated with the root canal
- FIG. 7 shows tissue formation in dentinal cylinders after transplantation of dental pulp cells.
- Sodium hypochlorite-treated dentin is shown in the left column.
- EDTA-treated dentin is shown in the right column.
- Figures (C) and (D) are illustrations after HE staining.
- Figures (E) and (F) are representations of Masson's trichrome stain. Tissue formation is visible in the middle of the cylinder (A, B).
- 0.5 ml of the prepared solution was placed in a zip-sealed PE bag (40 mm x 60 mm, DMG No. 101207) equipped with a filter paper. After sealing the bag, it is irradiated with UV light (254 nm, UV hand lamp, distance lower edge of device - PE bag: 17 mm) for 15, 30, 60, 90 and 120 min. After the end of irradiation, the filter paper was removed from the PE bag and rinsed twice with 10 ml of HPLC water (Baker 4218). These rinse solutions were placed in a 100 mL volumetric flask.
- the remaining sample remaining in the PE bag was also transferred to the 100 ml volumetric flask and the PE bag was rinsed twice with 5 ml of HPLC water each time. These rinsing solutions were also transferred to the volumetric flask. The volumetric flask was filled to the mark and a sample was analyzed by HPLC (Waters Alliance 2695 with UV detector Waters 2998) (HPLC method: Application No. 119780 "Complexing Agents acc
- the starting value (100%) is a solution of 500 ⁇ M 0.1 M EDTA solution (Merck, Darmstadt) in 100.0 ml of HPLC water.
- the EDTA degradation was determined as a double determination (with two PE bags per irradiation period).
- Example 12 Degradation rate of EDTA by means of UV light
- Example 11 a solution according to Example 11, to which 10 ml of HPLC water had been added instead of 5 ml of the FeC13 and 5 ml of the CaC12 solution and which was investigated by the method described in Example 11, showed no degradation after 15 minutes 20 min and after 90 min less than 40% of the EDTA were degraded.
- Example 13 Degradation rate of EDTA by FeCl3
- Example 14 Degradation rate of EDTA using FeCl3, UV light and ion exchanger
- Example 11 was repeated with the difference that instead of the filter paper a IonenonenonerpapierstMail (35 mm x 57 mm, Schleicher & Schuell 589 1 Schwarz band ⁇ ash free, Lot Bez. DU0901-1 or Whatman DE81 grade Cat.No. 3658-915, Lot No. F1646846) was contained in the PE bag.
- the EDTA content only initially decreased faster than in Example 11. It was 30% after 15 minutes.
- Example 15 Determination of Protein Breakdown After the end of the irradiation (see Example 11), a sample was taken from the PE bags and stored cool in brown glass vials (refrigerator).
- the protein concentration dropped to 80% after 30 minutes and to 65% after 90 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112014001245.9T DE112014001245B4 (de) | 2013-03-12 | 2014-02-28 | Verfahren und Kit zur Herstellung von Biomaterial zur Geweberegeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013204212.4 | 2013-03-12 | ||
DE102013204212.4A DE102013204212A1 (de) | 2013-03-12 | 2013-03-12 | Verfahren und Kit zur Herstellung von Biomaterial zur Geweberegeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014139809A1 true WO2014139809A1 (de) | 2014-09-18 |
Family
ID=50236157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/054005 WO2014139809A1 (de) | 2013-03-12 | 2014-02-28 | Verfahren und kit zur herstellung von biomaterial zur geweberegeneration |
Country Status (2)
Country | Link |
---|---|
DE (2) | DE102013204212A1 (de) |
WO (1) | WO2014139809A1 (de) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009028A1 (en) * | 1994-09-22 | 1996-03-28 | Pendine International Ltd. | Dental cavity conditioning |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120148538A1 (en) * | 2010-12-13 | 2012-06-14 | Snu R&Db Foundation | Composition for hard tissue formation and, dentin or pulp regeneration containing ameloblast, apical bud cell or its culture fluid as an active ingredient |
-
2013
- 2013-03-12 DE DE102013204212.4A patent/DE102013204212A1/de not_active Withdrawn
-
2014
- 2014-02-28 WO PCT/EP2014/054005 patent/WO2014139809A1/de active Application Filing
- 2014-02-28 DE DE112014001245.9T patent/DE112014001245B4/de active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009028A1 (en) * | 1994-09-22 | 1996-03-28 | Pendine International Ltd. | Dental cavity conditioning |
Non-Patent Citations (5)
Title |
---|
ANONYMOUS: "Die Wurzelkanalspülung", October 2006 (2006-10-01), XP002725599, Retrieved from the Internet <URL:http://www.dgzmk.de/uploads/tx_szdgzmkdocuments/DGZMK_Stellungnahme_Wurzelkanalspuelung_10_2006.pdf> * |
CHIAKI KITAMURA ET AL: "Local Regeneration of Dentin-Pulp Complex Using Controlled Release of FGF-2 and Naturally Derived Sponge-Like Scaffolds", INTERNATIONAL JOURNAL OF DENTISTRY, vol. 33, no. 11, 1 January 2012 (2012-01-01), pages 1277 - 8, XP055122392, ISSN: 1687-8728, DOI: 10.1016/j.dental.2006.01.005 * |
D TZIAFAS ET AL: "Induction of odontoblast-like cell differentiation in dog dental pulps after in vivo implantation of dentine matrix components", ARCHIVES OF ORAL BIOLOGY, 1 January 1995 (1995-01-01), ENGLAND, pages 883 - 893, XP055122437, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/0003996995000692> DOI: 10.1016/0003-9969(95)00069-2 * |
KERSTIN M. GALLER ET AL: "A Customized Self-Assembling Peptide Hydrogel for Dental Pulp Tissue Engineering", TISSUE ENGINEERING PART A, vol. 18, no. 1-2, 1 January 2012 (2012-01-01), pages 176 - 184, XP055122407, ISSN: 1937-3341, DOI: 10.1089/ten.tea.2011.0222 * |
SMITH A J ET AL: "Odontoblast stimulation in ferrets by dentine matrix components", ARCHIVES OF ORAL BIOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 39, no. 1, 1 January 1994 (1994-01-01), pages 13 - 22, XP026167593, ISSN: 0003-9969, [retrieved on 19940101], DOI: 10.1016/0003-9969(94)90029-9 * |
Also Published As
Publication number | Publication date |
---|---|
DE112014001245B4 (de) | 2022-01-20 |
DE102013204212A1 (de) | 2014-10-02 |
DE112014001245A5 (de) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0920341B1 (de) | Verfahren zur herstellung von wirkstoffhaltigen knochenzementen | |
DE2507933C2 (de) | ||
DE69823361T2 (de) | Herstellung von kollagen | |
EP0701824B1 (de) | Verfahren zur Herstellung von wirkstoffhaltigen Knochenzementen | |
EP2037972B1 (de) | Verwendung von gelatine und transglutaminase zur herstellung eines vernetzenden medizinischen klebers | |
EP0242672B1 (de) | Tricalciumphosphat für Implantationsmaterialien | |
EP2222327B1 (de) | Topische anwendung und formulierung von erythropoietin für die wundheilung der haut | |
EP2143771B1 (de) | Klebstoffzusammensetzung, insbesondere zur verwendung in der chirurgischen medizin | |
DE19646782C2 (de) | Bioresorbierbare Polymerisationsprodukte aus strahlungshärtbaren Bindemittelsystemen | |
EP2273997A2 (de) | Verfahren und zusammensetzung zur regeneration von gewebe mit hilfe von stamm- oder knochenmarkzellen | |
DE4414755C2 (de) | Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung | |
DE102005034420A1 (de) | Gelartiges Material zur Füllung von Knochen- und/oder Knorpeldefekten | |
DE2854490C2 (de) | Knochenersatzmaterial mit verbesserter biologischer Stabilität auf Basis von Kollagen | |
DE19904785A1 (de) | Verfahren zur Herstellung von stabilem Alginatmaterial | |
EP2236162A2 (de) | Bioaktiver Knochenzement und Verfahren zu seiner Herstellung | |
CA2958211A1 (en) | Extracellular matrix compositions | |
WO2013079443A1 (de) | Regenerations-hilfe für knochendefekte | |
DE3409372A1 (de) | Material zum vitalisieren von implantatoberflaechen | |
DE102007013040A1 (de) | Zahnbleichsystem | |
DE112014001245B4 (de) | Verfahren und Kit zur Herstellung von Biomaterial zur Geweberegeneration | |
DE102009042036B4 (de) | Verwendung einer lichthärtenden, biokompatiblen und biologisch abbaubaren Polymermischung | |
WO2016097040A1 (de) | Mehrkomponentenklebstoff zur herstellung eines adhäsivhydrogels | |
DE3517456C2 (de) | ||
DE60018607T2 (de) | Knochenbildendes material | |
EP3218025B1 (de) | Herstellung und isolierung einer nativen humanen dermalen extrazellulären matrix |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14708230 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 112014001245 Country of ref document: DE Ref document number: 1120140012459 Country of ref document: DE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: R225 Ref document number: 112014001245 Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14708230 Country of ref document: EP Kind code of ref document: A1 |